Zydus Lifesciences · NSE: ZYDUSLIFE · BSE: 532321

Q4 FY24 results · Jan–Mar 2024

Zydus Lifesciences reported revenue from operations of ₹5,533.80 crore (up 10.4% from Q4 FY23) and net profit of ₹1,246.10 crore (up 247.9% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q4 FY24	Q4 FY23	YoY	Q3 FY24	QoQ
Revenue from operations	5,533.80	5,010.60	+10.4%	4,505.20	+22.8%
Other income	156.40	37.80	+313.8%	37.70	+314.9%
Total income	5,690.20	5,048.40	+12.7%	4,542.90	+25.3%
Profit before share of associates & JVs and tax	1,547.00	485.80	+218.4%	925.50	+67.2%
Share of profit/(loss) of associates & JVs	17.10	11.80		56.40
Net profit for the period	1,246.10	358.20	+247.9%	789.90	+57.8%
Attributable to shareholders of the company	63.80	296.60	−78.5%	789.60	−91.9%
EPS, basic (₹)	11.69	2.93	+299.0%	7.80	+49.9%
Net margin (%)	22.5	7.1		17.5

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q4 FY24	Q4 FY23	YoY	Q3 FY24	QoQ
Revenue from operations	3,332.40	2,579.30	+29.2%	2,371.30	+40.5%
Other income	361.10	251.20	+43.8%	106.80	+238.1%
Total income	3,693.50	2,830.50	+30.5%	2,478.10	+49.0%
Profit before tax	1,684.90	615.00	+174.0%	574.30	+193.4%
Net profit for the period	1,405.20	490.70	+186.4%	450.40	+212.0%
EPS, basic (₹)	13.89	4.85	+186.4%	4.45	+212.1%
Net margin (%)	42.2	19.0		19.0

Consolidated

Filed with BSE: 18 May 2024, 09:10 IST
Board meeting: 17 May 2024
Period: 01 Jan 2024 to 31 Mar 2024
Review status: Audited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 18 May 2024, 09:10 IST
Board meeting: 17 May 2024
Period: 01 Jan 2024 to 31 Mar 2024
Review status: Audited
Source: XBRL filing on BSE